Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 726 of 5804
-
Immunotherapy cocktail aims to boost breast cancer remission before surgery
Disease control OngoingThis is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple negative breast cancer (TNBC).
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to tame tough prostate cancer
Disease control OngoingThis phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as c…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo aims to outsmart lung Cancer's growth signals
Disease control Recruiting nowThis phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is in…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail aims to outsmart advanced breast cancer
Disease control OngoingDESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo therapy aims to stop rare HER2-positive salivary gland cancer in its tracks
Disease control Recruiting nowThis research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of st…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Brain surgery boost: radioactive seeds may keep tumors from returning
Disease control OngoingThe purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after sur…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Second chance: new combo targets relapsed CLL after venetoclax fails
Disease control Recruiting nowFixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of first-line tre…
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to tame recurrent head and neck cancer
Disease control OngoingThe purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Radiation 'Re-Priming' could supercharge CAR-T therapy in stubborn lymphoma
Disease control CompletedThis is a single-arm open-label phase I/II trial studying the safety and efficacy of focal 're-priming' radiation therapy (RT) to FDG-avid residual sites of disease in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) patients with incomplete response (IR) to CAR T-cell therapy …
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo may keep breast cancer from coming back
Disease control OngoingPOETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine ther…
Phase: PHASE3 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo therapy shows promise for aggressive breast cancer
Disease control CompletedBreast cancer is one of the most common cancers in women. 20-30 % of all breast cancer patients are faced with advanced disease, comprising both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). 80% of MBC cases are diagnosed as hormone receptor (HR) posit…
Sponsor: Technical University of Munich • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Which therapy works best for kids with MIS-C?
Disease control CompletedIn March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be kn…
Phase: PHASE2, PHASE3 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for advanced lung cancer: experimental drug DS-1062a takes on standard chemo
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Head-to-Head: which biologic works better for tough psoriatic arthritis?
Disease control CompletedThe purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New device aims to restore heart function in failing hearts
Disease control TerminatedProspective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Phase: NA • Sponsor: Ancora Heart, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough lung cancer
Disease control OngoingCombination of concomitant Radio-Chemotherapy showed a significant improvement (Takada) of OS and PFS in limited disease SCLC patients. This clinical trial is a prospective, multicenter, randomized, open-label, parallel group phase II investigator initiated trial (ITT) to evaluat…
Phase: PHASE2 • Sponsor: Michael Hopp • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo shows promise against hereditary breast cancer
Disease control OngoingThis research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for bladder cancer patients avoiding bladder removal
Disease control OngoingThe purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant h…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a cancer drug make stem cell transplants safer for myelofibrosis patients?
Disease control OngoingThis phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and secondary myelofibrosis. Donor …
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC